Compare Dolby Laboratories, Inc. (DLB) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Enveric Biosciences Inc — how do they compare? Dolby Laboratories, Inc. trades at $58.9 (market cap $5.47B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.80M). The key difference: Dolby Laboratories, Inc. is far larger — about 804.4× Enveric Biosciences Inc's market cap, and Dolby Laboratories, Inc. pays a 2.46% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and Enveric Biosciences Inc for 14 Days on average.
| DLB | ENVB | |
|---|---|---|
Market Cap | $5.47B | $6.80M |
Volume | 1,058,284 | 64,867 |
Sector | Technology | Health |
52-Week High | $70.09 | $10.80 |
52-Week Low | $48.51 | $1.27 |
Typical Hold Time | 98 Days | 14 Days |
Enterprise Value | $4.85B | -$1.49M |
Dividend Yield | 2.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $58.35, down 0.19% with bearish technical signals. The company maintains strong profitability with 87.61% gross margins and has beaten earnings estimates for three consecutive quarters. Recent developments include expanded partnerships with Meta and leadership transition to new CEO Marc Whitten. Cash flow improved significantly in 2025 with $472M operating cash flow.
DLB presents a mixed outlook with strong fundamentals but technical weakness. The 47% upside to $90.33 consensus target offers potential, though near-term execution risks and licensing volatility remain concerns. Revenue stability around $1.3B and premium valuation metrics require continued innovation execution to justify current multiples.
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
